ProShares Ultra Nasdaq Biotechnology (BIB) Leveraged/Inverse
$109.80
▼ -0.67 (-0.61%)
1-day change
$62.04 – $126.40
52-week range
Holdings data is not available for this fund yet.
BIB Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
Performance as of Oct. 2, 2026
| Period | Price return | Total return |
|---|---|---|
| 1M | ▼ -9.84% | ▼ -9.78% |
| 3M | ▲ +2.77% | ▲ +2.84% |
| 6M | ▲ +34.28% | ▲ +34.37% |
| YTD | ▲ +37.63% | ▲ +37.74% |
| 1Y | ▲ +73.21% | ▲ +73.64% |
| 3Y | ▲ +135.47% | ▲ +142.03% |
| 5Y | ▲ +20.16% | ▲ +23.54% |
| Max | ▲ +1362.31% | ▲ +1406.10% |
Volatility 1Y42.75%
Volatility 3Y41.86%
Max drawdown 3Y
-45.99%
Beta 3Y0.85
Sharpe 1Y*1.50
Total return assumes dividends are reinvested. Returns are not benchmarked against an index. * Sharpe ratio is computed with a 0% risk-free rate.
Fund flows (SEC-reported)
Last month (May 2026)
-$4.8M
Quarter ending May 2026
-$13.9M
Trailing 12 months
-$12.0M
Based on the fund's own SEC Form N-PORT monthly flow disclosures (Item C.9 "Flow Information") — sales minus redemptions, reinvested distributions excluded. This is a different, independent metric from the "Net flows" estimate above (which is derived from daily shares-outstanding changes). SEC N-PORT filing lag is up to ~60 days; the most recent month/quarter may not yet be fully reflected.
Full composition 267 holdings
| Name | CUSIP | Value | % | Balance | Category | Country |
|---|---|---|---|---|---|---|
| Legend Biotech Corp. | 52490G102 | $85K | 0.12 | 3,122 | EC | KY |
| Kodiak Sciences, Inc. | 50015M109 | $83K | 0.11 | 2,255 | EC | US |
| BioCryst Pharmaceuticals, Inc. | 09058V103 | $83K | 0.11 | 9,271 | EC | US |
| Kiniksa Pharmaceuticals International plc | · | $82K | 0.11 | 1,698 | EC | GB |
| Aurinia Pharmaceuticals, Inc. | 05156V102 | $75K | 0.10 | 4,914 | EC | CA |
| Ocular Therapeutix, Inc. | 67576A100 | $73K | 0.10 | 8,049 | EC | US |
| Novocure Ltd. | · | $72K | 0.10 | 4,209 | EC | JE |
| Pharvaris NV | · | $71K | 0.10 | 2,367 | EC | NL |
| Sionna Therapeutics, Inc. | 829401108 | $71K | 0.10 | 1,651 | EC | US |
| ADMA Biologics, Inc. | 000899104 | $70K | 0.10 | 8,805 | EC | US |
| Rapport Therapeutics, Inc. | 75383L102 | $70K | 0.09 | 1,764 | EC | US |
| Zymeworks, Inc. | 98985Y108 | $70K | 0.09 | 2,766 | EC | US |
| Recursion Pharmaceuticals, Inc. | 75629V104 | $69K | 0.09 | 19,297 | EC | US |
| Sarepta Therapeutics, Inc. | 803607100 | $69K | 0.09 | 3,875 | EC | US |
| AbCellera Biologics, Inc. | 00288U106 | $69K | 0.09 | 11,209 | EC | CA |
| Harmony Biosciences Holdings, Inc. | 413197104 | $68K | 0.09 | 2,140 | EC | US |
| Nurix Therapeutics, Inc. | 67080M103 | $68K | 0.09 | 3,802 | EC | US |
| Trevi Therapeutics, Inc. | 89532M101 | $67K | 0.09 | 4,742 | EC | US |
| Novavax, Inc. | 670002401 | $66K | 0.09 | 6,023 | EC | US |
| Tyra Biosciences, Inc. | 90240B106 | $66K | 0.09 | 1,974 | EC | US |
| uniQure NV | · | $66K | 0.09 | 2,305 | EC | NL |
| Stoke Therapeutics, Inc. | 86150R107 | $65K | 0.09 | 2,111 | EC | US |
| ANI Pharmaceuticals, Inc. | 00182C103 | $65K | 0.09 | 830 | EC | US |
| Syndax Pharmaceuticals, Inc. | 87164F105 | $64K | 0.09 | 3,261 | EC | US |
| Agios Pharmaceuticals, Inc. | 00847X104 | $64K | 0.09 | 2,166 | EC | US |
| Genmab A/S | 372303206 | $63K | 0.09 | 2,379 | EC | DK |
| Vericel Corp. | 92346J108 | $62K | 0.08 | 1,875 | EC | US |
| Iovance Biotherapeutics, Inc. | 462260100 | $62K | 0.08 | 15,232 | EC | US |
| Intellia Therapeutics, Inc. | 45826J105 | $61K | 0.08 | 4,369 | EC | US |
| AtaiBeckley, Inc. | 04650F101 | $61K | 0.08 | 13,429 | EC | US |
| Taysha Gene Therapies, Inc. | 877619106 | $59K | 0.08 | 10,128 | EC | US |
| Innoviva, Inc. | 45781M101 | $59K | 0.08 | 2,740 | EC | US |
| Amylyx Pharmaceuticals, Inc. | 03237H101 | $58K | 0.08 | 4,059 | EC | US |
| AnaptysBio, Inc. | 032724106 | $57K | 0.08 | 1,023 | EC | US |
| Precigen, Inc. | 74017N105 | $57K | 0.08 | 13,080 | EC | US |
| Inhibrx Biosciences, Inc. | 45720N103 | $56K | 0.08 | 537 | EC | US |
| Monte Rosa Therapeutics, Inc. | 61225M102 | $56K | 0.08 | 2,818 | EC | US |
| Vir Biotechnology, Inc. | 92764N102 | $55K | 0.08 | 5,810 | EC | US |
| GH Research plc | · | $55K | 0.07 | 2,294 | EC | IE |
| Ardelyx, Inc. | 039697107 | $55K | 0.07 | 9,066 | EC | US |
| Fortrea Holdings, Inc. | 34965K107 | $53K | 0.07 | 3,455 | EC | US |
| MBX Biosciences, Inc. | 55287L101 | $52K | 0.07 | 1,658 | EC | US |
| Bicara Therapeutics, Inc. | 055477103 | $51K | 0.07 | 2,343 | EC | US |
| KalVista Pharmaceuticals, Inc. | 483497103 | $50K | 0.07 | 1,870 | EC | US |
| Septerna, Inc. | 81734D104 | $50K | 0.07 | 1,657 | EC | US |
| UroGen Pharma Ltd. | · | $49K | 0.07 | 1,730 | EC | IL |
| Harrow, Inc. | 415858109 | $48K | 0.07 | 1,370 | EC | US |
| Maze Therapeutics, Inc. | 578784100 | $47K | 0.06 | 1,778 | EC | US |
| Immunocore Holdings plc | 45258D105 | $47K | 0.06 | 1,621 | EC | GB |
| ArriVent Biopharma, Inc. | 04272N102 | $46K | 0.06 | 1,527 | EC | US |
Dividends 13 payments
0.20%TTM yield
$0.23TTM payout / share
Quarterly
(est.)
| Ex-date | Amount / share |
|---|---|
| Sept. 23, 2026 | $0.0830 |
| March 25, 2026 | $0.0070 |
| Dec. 24, 2025 | $0.1350 |
| Sept. 24, 2025 | $0.1810 |
| June 25, 2025 | $0.1710 |
| March 26, 2025 | $0.1310 |
| Dec. 23, 2024 | $0.3960 |
| Sept. 25, 2024 | $0.1530 |
| June 26, 2024 | $0.2650 |
| March 20, 2024 | $0.0400 |
| Dec. 20, 2023 | $0.0380 |
| Dec. 22, 2022 | $0.0200 |
| Sept. 21, 2010 | $0.0110 |
Institutional owners (13F) 22 filers
Institutions that report holding this ETF in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
| Institution | Value | % of tracked 13F | Shares | Type | As of |
|---|---|---|---|---|---|
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $785,973 | 21.94% | 7,802 | Shares | June 30, 2026 |
| Capital Investment Advisors, LLC | $599,013 | 16.72% | 5,946 | Shares | June 30, 2026 |
| Kaizen Financial Strategies | $535,554 | 14.95% | 5,315 | Shares | June 30, 2026 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $413,034 | 11.53% | 4,100 | Call option | June 30, 2026 |
| Palumbo Wealth Management LLC | $402,960 | 11.25% | 4,000 | Shares | June 30, 2026 |
| CITADEL ADVISORS LLC | $302,220 | 8.44% | 3,000 | Call option | June 30, 2026 |
| Jump Financial, LLC | $257,189 | 7.18% | 2,553 | Shares | June 30, 2026 |
| TOTH FINANCIAL ADVISORY CORP | $102,957 | 2.87% | 1,022 | Shares | June 30, 2026 |
| FRANKLIN RESOURCES INC | $70,115 | 1.96% | 696 | Shares | June 30, 2026 |
| PNC Financial Services Group, Inc. | $50,370 | 1.41% | 500 | Shares | June 30, 2026 |
| Ashton Thomas Private Wealth, LLC | $37,576 | 1.05% | 373 | Shares | June 30, 2026 |
| Truvestments Capital LLC | $12,593 | 0.35% | 125 | Shares | June 30, 2026 |
| Axiom Investment Management LLC | $5,037 | 0.14% | 50 | Shares | June 30, 2026 |
| Qube Research & Technologies Ltd | $4,936 | 0.14% | 49 | Shares | June 30, 2026 |
| SIMPLEX TRADING, LLC | $1,309 | 0.04% | 13 | Shares | June 30, 2026 |
| CHASE INVESTMENT COUNSEL CORP | $241 | 0.01% | 2,400 | Shares | June 30, 2026 |
| Rockefeller Capital Management L.P. | $201 | 0.01% | 2 | Shares | June 30, 2026 |
| MORGAN STANLEY | $131 | 0.00% | 1 | Shares | June 30, 2026 |
| UBS Group AG | $101 | 0.00% | 1 | Shares | June 30, 2026 |
| WELLS FARGO & COMPANY/MN | $65 | 0.00% | 1 | Shares | June 30, 2026 |
| Harel Insurance Investments & Financial Services Ltd. | $20 | 0.00% | 198 | Shares | June 30, 2026 |
| ROYAL BANK OF CANADA | $0 | 0.00% | 1 | Shares | June 30, 2026 |